

- 22 -

**WHAT IS CLAIMED IS:**

1. A method for diagnosing an angina condition in a patient, said method comprising:

- a) stimulating lymphocytes from said patient,
- b) determining the frequency of cytokine-producing cells among said lymphocytes,
- c) comparing said frequency of cytokine-producing cells to a reference frequency to obtain information about said angina condition, and
- d) classifying said angina condition as stable or unstable based on said information.

2. The method of claim 1, wherein said lymphocytes are CD4<sup>+</sup> cells.

3. The method of claim 1, wherein said lymphocytes are CD8<sup>+</sup> cells.

4. The method of claim 1, wherein said stimulating comprises contacting said lymphocytes with a phorbol ester.

5. The method of claim 4, wherein said phorbol ester comprises phorbol myristate acetate.

6. The method of claim 1, wherein said stimulating comprises contacting said lymphocytes with a calcium ionophore.

7. The method of claim 6, wherein said calcium ionophore comprises ionomycin.

8. The method of claim 1, wherein said frequency of cytokine-producing cells comprises the percent of CD4<sup>+</sup> cells producing INF- $\gamma$ .

- 23 -

9. The method of claim 1, wherein said frequency of cytokine-producing cells comprises the percent of CD8<sup>+</sup> cells producing INF- $\gamma$ .
10. The method of claim 1, wherein said frequency of cytokine-producing cells comprises the percent of CD4<sup>+</sup> cells producing IL-2.
11. The method of claim 1, wherein said frequency of cytokine-producing cells comprises the percent of CD4<sup>+</sup> cells producing IL-4.
12. The method of claim 1, wherein said reference frequency comprises the median frequency of cytokine-producing cells derived from a population.
13. The method of claim 12, wherein said median frequency of cytokine-producing cells comprises the median percent of CD4<sup>+</sup> cells producing INF- $\gamma$  derived from said population.
14. The method of claim 12, wherein said median frequency of cytokine-producing cells comprises the median percent of CD8<sup>+</sup> cells producing INF- $\gamma$  derived from said population.
15. The method of claim 12, wherein said median frequency of cytokine-producing cells comprises the median percent of CD4<sup>+</sup> cells producing IL-2 derived from said population.
16. The method of claim 12, wherein said median frequency of cytokine-producing cells comprises the median percent of CD4<sup>+</sup> cells producing IL-4 derived from said population.
17. The method of claim 12, wherein said population comprises a population of unstable angina patients.

- 24 -

18. The method of claim 12, wherein said population comprises a population of stable angina patients.

19. The method of claim 12, wherein said population comprises a population of healthy individuals.

20. A method for determining the predisposition of an individual to have a stable or unstable angina condition, said method comprising:

- a) stimulating lymphocytes from said individual,
- b) determining the frequency of cytokine-producing cells among said lymphocytes,
- c) comparing said frequency of cytokine-producing cells to a reference frequency to obtain information about said individual, and
- d) classifying said individual as being predisposed to have a stable or unstable angina condition based on said information.

21. A method for diagnosing an angina condition in a patient, said method comprising:

- a) determining the frequency of CD4<sup>+</sup>/CD28<sup>null</sup> cells in said patient,
- d) comparing said frequency of CD4<sup>+</sup>/CD28<sup>null</sup> cells to a reference frequency to obtain information about said angina condition, and
- c) classifying said angina condition as stable or unstable based on said information.

22. The method of claim 21, wherein said frequency of CD4<sup>+</sup>/CD28<sup>null</sup> cells comprises the percent of CD4<sup>+</sup> cells that are CD28 negative.

23. The method of claim 21, wherein said reference frequency is derived from the CD4<sup>+</sup>/CD28<sup>null</sup> cell frequencies from a population.

- 25 -

24. The method of claim 23, wherein said population comprises a population of unstable angina patients.

25. The method of claim 23, wherein said population comprises a population of stable angina patients.

26. The method of claim 23, wherein said population comprises a population of healthy individuals.

27. The method of claim 23, wherein said reference frequency comprises the percent of CD4<sup>+</sup> cells that are CD28 negative.

28. The method of claim 27, wherein said reference frequency is greater than about 2.0 percent.

29. The method of claim 27, wherein said reference frequency is less than about 2.0 percent.

30. A method for determining the predisposition of an individual to have a stable or unstable angina condition, said method comprising:

a) determining the frequency of CD4<sup>+</sup>/CD28<sup>null</sup> cells in said individual,

d) comparing said frequency of CD4<sup>+</sup>/CD28<sup>null</sup> cells to a reference

frequency to obtain information about said individual, and

c) classifying said individual as being predisposed to have a stable or unstable angina condition based on said information.

31. A kit for providing diagnostic information about an angina condition in a patient, said kit comprising a binding pair member and a reference chart, said binding pair member having specific binding affinity for a cytokine such that the frequency of cells producing said cytokine from said patient is determinable, and

- 26 -

wherein said reference chart contains information about cytokine-producing cell frequencies such that an indication of the stable or unstable nature of said angina condition is determinable based on said frequency of cells producing said cytokine from said patient.

32. A kit for determining the predisposition of an individual to have a stable or unstable angina condition, said kit comprising a binding pair member and a reference chart, said binding pair member having specific binding affinity for a cytokine such that the frequency of cells producing said cytokine from said individual is determinable, and wherein said reference chart contains information about cytokine-producing cell frequencies such that an indication of said predisposition is determinable based on said frequency of cells producing said cytokine from said individual.

33. A kit for providing diagnostic information about an angina condition in a patient, said kit comprising a binding pair member and a reference chart, said binding pair member having specific binding affinity for a CD4<sup>+</sup>/CD28<sup>null</sup> cell marker such that the frequency of CD4<sup>+</sup>/CD28<sup>null</sup> cells in said patient is determinable, and wherein said reference chart contains information about CD4<sup>+</sup>/CD28<sup>null</sup> cell frequencies such that an indication of the stable or unstable nature of said angina condition is determinable based on said frequency of CD4<sup>+</sup>/CD28<sup>null</sup> cells in said patient.

34. A kit for determining the predisposition of an individual to have a stable or unstable angina condition, said kit comprising a binding pair member and a reference chart, said binding pair member having specific binding affinity for a CD4<sup>+</sup>/CD28<sup>null</sup> cell marker such that the frequency of CD4<sup>+</sup>/CD28<sup>null</sup> cells in said individual is determinable, and wherein said reference chart contains information about CD4<sup>+</sup>/CD28<sup>null</sup> cell frequencies such that an indication of said predisposition is determinable based on said frequency of CD4<sup>+</sup>/CD28<sup>null</sup> cells in said individual.